| Literature DB >> 17181857 |
Manuela Sironi1, Giorgia Menozzi, Giacomo P Comi, Matteo Cereda, Rachele Cagliani, Nereo Bresolin, Uberto Pozzoli.
Abstract
BACKGROUND: Transposable elements (TEs) represent more than 45% of the human and mouse genomes. Both parasitic and mutualistic features have been shown to apply to the host-TE relationship but a comprehensive scenario of the forces driving TE fixation within mammalian genes is still missing.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17181857 PMCID: PMC1794433 DOI: 10.1186/gb-2006-7-12-r120
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
GO terms associated with TE-poor genes
| Under-represented TE type | |||||||||||||||||||
| GO term | Description | Alu | L1 | L2 | LTR | DNA transp. | MIR | ||||||||||||
| N | MCS | IG | N | MCS | IG | N | MCS | IG | N | MCS | IG | N | MCS | IG | N | MCS | IG | ||
| GO:0003676 | Nucleic acid binding | - | - | - | - | - | - | 468 | 0.88* | -0.44* | 598 | 0.86* | -0.27* | - | - | - | 327 | 1.07 | -0.29* |
| GO:0003677 | DNA binding | - | - | - | - | - | - | - | - | - | 394 | 1.27* | -0.17 | - | - | - | 219 | 1.6* | -0.34* |
| GO:0003723 | RNA binding | - | - | - | - | - | - | 131 | 0.08 | -0.49* | 153 | 0.13 | -0.42* | - | - | - | 91 | 0.03 | -0.12 |
| GO:0003700 | Transcription factor activity | 138 | 2.45* | -0.63* | 171 | 1.9* | -0.51* | 160 | 2.1* | -0.41* | 220 | 1.82* | -0.09 | 165 | 2.18* | -0.65* | 125 | 2.23* | -0.76* |
| GO:0030528 | Transcription regulator activity | 159 | 2.35* | -0.59* | - | - | - | - | - | - | 279 | 1.57* | -0.1 | - | - | - | 152 | 2.04* | -0.67* |
| GO:0004871 | Signal transducer activity | 348 | 0.32 | -0.45* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0004888 | Transmembrane receptor activity | 138 | 0.23 | -0.31 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0005102 | Receptor binding | 137 | 0.5 | -0.57* | 170 | 0.29 | 0.03 | 149 | 0.24 | 0.14 | 192 | 0.33 | 0.2 | 155 | 0.32 | -0.02 | - | - | - |
| GO:0001664 | G-protein-coupled receptor binding | - | - | - | 25 | -0.14 | -0.23 | - | - | - | - | - | - | 26 | -0.16 | -0.1 | - | - | - |
| GO:0008083 | Growth factor activity | 47 | 0.98 | -0.16 | - | - | - | - | - | - | 64 | 0.73 | 0.45* | - | - | - | - | - | - |
| GO:0005125 | Cytokine activity | 69 | 0.59 | -0.71* | 84 | 0.29 | -0.36 | - | - | - | 91 | 0.44 | 0.48* | 76 | 0.42 | 0.24 | - | - | - |
| GO:0008009 | Chemokine activity | - | - | - | 25 | -0.14 | -0.23 | - | - | - | - | - | - | 26 | -0.16 | -0.1 | - | - | - |
| GO:0042379 | Chemokine receptor binding | - | - | - | 25 | -0.14 | -0.23 | - | - | - | - | - | - | 26 | -0.16 | -0.1 | - | - | - |
| GO:0005179 | Hormone activity | 33 | 0.49 | -0.71 | - | - | - | 41 | 0.11* | -0.44 | - | - | - | 34 | 0.19* | -0.47 | 27 | 0.49 | -0.64 |
| GO:0005184 | Neuropeptide hormone activity | 10 | -0.12 | 0.27 | - | - | - | 11 | 0.01 | 0.68 | - | - | - | - | - | - | - | - | - |
| GO:0004252 | Serine-type endopeptidase activity | - | - | - | 50 | -0.34* | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0004263 | Chymotrypsin activity | - | - | - | 38 | -0.45* | -0.1 | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0004295 | Trypsin activity | - | - | - | 39 | -0.45* | -0.21 | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0003735 | Structural constituent of ribosome | - | - | - | 100 | -0.34* | -0.25 | 89 | -0.41* | -0.72* | 116 | -0.37* | -0.58* | 79 | -0.35* | -0.5 | 63 | -0.33* | -0.47 |
| GO:0005198 | Structural molecule activity | - | - | - | 212 | -0.04 | -0.4* | 192 | -0.11* | -0.43* | 260 | -0.07 | -0.2 | - | - | - | - | - | - |
| GO:0007275 | Development | 335 | 1.41* | -0.55* | 410 | 1.13* | -0.45* | 386 | 1.19* | -0.23 | 512 | 1.09* | 0.1 | 384 | 1.32* | -0.45* | 258 | 1.58* | -0.48* |
| GO:0009653 | Morphogenesis | 222 | 1.24* | -0.48* | - | - | - | - | - | - | 334 | 0.94* | 0.21* | - | - | - | - | - | - |
| GO:0009887 | Organogenesis | 186 | 1.03* | -0.46* | - | - | - | - | - | - | 270 | 0.8* | 0.22* | - | - | - | - | - | - |
| GO:0009888 | Histogenesis | - | - | - | - | - | - | - | - | - | 47 | 0.49 | 0.46 | - | - | - | - | - | - |
| GO:0008544 | Epidermis development | 24 | -0.27 | -1.4* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0001501 | Skeletal development | 36 | 1.4* | -0.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0007267 | Cell-cell signaling | 137 | 0.71* | -0.27 | 162 | 0.69* | 0.03 | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0007166 | Cell surface receptor linked signal transduction | 161 | 0.29* | -0.45* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0007186 | G-protein coupled receptor protein signaling pathway | 93 | 0.17 | -0.51* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0006952 | Defense response | 172 | 0.13* | -0.75* | 217 | -0.08* | -0.16 | 202 | -0.11* | -0.19 | 259 | 0* | 0.01 | 219 | -0.04* | -0.2 | - | - | - |
| GO:0006955 | Immune response | 155 | 0.17* | -0.7* | 201 | -0.08* | -0.19 | - | - | - | - | - | - | 202 | -0.05* | -0.17 | - | - | - |
| GO:0050896 | Response to stimulus | 268 | 0.13 | -0.61* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0009607 | Response to biotic stimulus | 187 | 0.1* | -0.69* | 240 | -0.1* | -0.21 | 222 | -0.14* | -0.16 | 290 | -0.05* | 0 | 235 | -0.07* | -0.25 | - | - | - |
| GO:0009613 | Response to pest, pathogen or parasite | 99 | -0.02* | -0.8* | - | - | - | - | - | - | - | - | - | 127 | -0.33* | -0.13 | - | - | - |
| GO:0043207 | Response to external biotic stimulus | 106 | -0.09* | -0.86* | - | - | - | - | - | - | - | - | - | 134 | -0.36* | -0.17 | - | - | - |
| GO:0006817 | Phosphate transport | 27 | -0.05 | -0.39 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0006820 | Anion transport | 41 | 0.03 | -0.47 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0015698 | Inorganic anion transport | 38 | 0.03 | -0.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0006350 | Transcription | - | - | - | - | - | - | - | - | - | 386 | 1.22* | -0.16 | - | - | - | 211 | 1.43* | -0.43* |
| GO:0045449 | Regulation of transcription | - | - | - | - | - | - | - | - | - | 365 | 1.31* | -0.15 | - | - | - | 198 | 1.53* | -0.45* |
| GO:0006351 | Transcription, DNA-dependent | - | - | - | - | - | - | - | - | - | 369 | 1.25* | -0.16 | - | - | - | 203 | 1.48* | -0.45* |
| GO:0006355 | Regulation of transcription, DNA-dependent | - | - | - | - | - | - | 267 | 1.38* | -0.23 | 355 | 1.31* | -0.16 | - | - | - | 196 | 1.53* | -0.46* |
| GO:0006139 | Nucleobase, nucleoside, nucleotide and nucleic acid metabolism | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 301 | 1.08 | -0.23 |
| GO:0019219 | Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism | - | - | - | - | - | - | - | - | - | 371 | 1.29* | -0.16 | - | - | - | 202 | 1.51* | -0.46* |
| GO:0019222 | Regulation of metabolism | - | - | - | - | - | - | 303 | 1.32* | -0.2 | 409 | 1.24* | -0.16 | - | - | - | 217 | 1.54* | -0.38* |
| GO:0006412 | Protein biosynthesis | - | - | - | 144 | -0.14 | -0.34 | - | - | - | 179 | -0.1* | -0.48* | - | - | - | - | - | - |
| GO:0050876 | Reproductive physiological process | 18 | 1.19 | -0.76 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GO:0000003 | Reproduction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44 | 0.09* | -0.38 |
| GO:0019953 | Sexual reproduction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43 | 0.06* | -0.38 |
| GO:0007276 | Gametogenesis | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39 | 0.14* | -0.39 |
| GO:0048232 | Male gamete generation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33 | 0.07* | -0.05 |
| GO:0007283 | Spermatogenesis | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33 | 0.07* | -0.05 |
Significant differences are marked with an asterisk. DNA transp., DNA transposon; N, number of contributing genes; MCS, fractional intronic MCS density deviation (see text); IG, fractional igTEna deviation (see text).
GO terms associated with TE-rich human genes
| Over-represented TE types | |||||||||
| GO term | Description | Alu | L1 | L2 | LTR | DNA transp. | MIR | ||
| N | MCS | IG | |||||||
| GO:0008009 | Chemokine activity | - | - | - | - | - | 9 | -0.91* | -0.66 |
| GO:0005125 | Cytokine activity | - | - | - | - | - | 24 | -0.42 | -0.13 |
| GO:0001584 | Rhodopsin-like receptor activity | - | - | - | - | - | 19 | -0.44 | 0.31 |
| GO:0042379 | Chemokine receptor binding | - | - | - | - | - | 9 | -0.91* | -0.66 |
| GO:0005102 | Receptor binding | - | - | - | - | - | 38 | -0.45 | -0.03 |
| GO:0001664 | G-protein-coupled receptor binding | - | - | - | - | - | 9 | -0.91* | -0.66 |
| GO:0050874 | Organismal physiological process | - | - | - | - | - | 89 | -0.57* | 0.01 |
| GO:0009607 | Response to biotic stimulus | - | - | - | - | - | 70 | -0.69* | 0.36 |
| GO:0006955 | Immune response | - | - | - | - | - | 60 | -0.67* | 0.23 |
| GO:0009611 | Response to wounding | - | - | - | - | - | 31 | -0.73* | 0.11 |
| GO:0006954 | Inflammatory response | - | - | - | - | - | 24 | -0.79* | 0.06 |
| GO:0006952 | Defense response | - | - | - | - | - | 66 | -0.7* | 0.3 |
| GO:0045087 | Innate immune response | - | - | - | - | - | 26 | -0.78* | 0.07 |
| GO:0016064 | Humoral defense mechanism | - | - | - | - | - | 14 | -0.65 | 0.24 |
| GO:0009617 | Response to bacteria | - | - | - | - | - | 13 | -0.83* | 0.34 |
| GO:0009613 | Response to pest, pathogen or parasite | - | - | - | - | - | 47 | -0.72* | 0.21 |
| GO:0043207 | Response to external biotic stimulus | - | - | - | - | - | 51 | -0.74* | 0.16 |
| GO:0006950 | Response to stress | - | - | - | - | - | 53 | -0.72* | 0.16 |
| GO:0042742 | Defense response to bacteria | - | - | - | - | - | 9 | -0.98* | 0.36 |
| GO:0009605 | Response to external stimulus | - | - | - | - | - | 65 | -0.76* | 0.19 |
| GO:0009620 | Response to fungi | - | - | - | - | - | 6 | -1* | 0.91 |
| GO:0009628 | Response to abiotic stimulus | - | - | - | - | - | 28 | -0.83* | 0.55 |
| GO:0042221 | Response to chemical substance | - | - | - | - | - | 27 | -0.83* | 0.7 |
| GO:0050896 | Response to stimulus | - | - | - | - | - | 85 | -0.71* | 0.31 |
| GO:0006968 | Cellular defense response | - | - | - | - | - | 14 | -0.64 | -0.14 |
| GO:0007267 | Cell-cell signaling | - | - | - | - | - | 37 | -0.26 | -0.32 |
| GO:0042330 | Taxis | - | - | - | - | - | 17 | -0.78* | -0.1 |
| GO:0006935 | Chemotaxis | - | - | - | - | - | 17 | -0.78* | -0.1 |
| GO:0030574 | Collagen catabolism | - | - | - | - | - | 7 | -0.69 | -0.77 |
Significant differences are marked with an asterisk. DNA transp., DNA transposon; N, number of contributing genes; MCS, fractional intronic MCS density deviation (see text); IG, fractional igTEna deviation (see text).
GO terms associated with TE-rich mouse genes
| Over-represented TE types | |||||||||||||
| GO term | Description | B1 | L1 | LTR | L2 | MIR | B2/ID/B4 | ||||||
| N | MCS | IG | N | MCS | IG | N | MCS | IG | |||||
| GO:0005215 | Transporter activity | - | - | - | 64 | -0.24 | 0.33 | - | - | - | - | - | - |
| GO:0005216 | Ion channel activity | - | - | - | - | - | - | 28 | 0.2 | -0.05 | - | - | - |
| GO:0015268 | Alpha-type channel activity | - | - | - | - | - | - | 33 | 0.13 | 0.12 | - | - | - |
| GO:0015267 | Channel or pore class transporter activity | - | - | - | - | - | - | 33 | 0.13 | 0.12 | - | - | - |
| GO:0005261 | Cation channel activity | - | - | - | - | - | - | 23 | 0.37* | -0.08 | - | - | - |
| GO:0005244 | Voltage-gated ion channel activity | - | - | - | - | - | - | 19 | 0.34 | -0.1 | - | - | - |
| GO:0030001 | Metal ion transport | - | - | - | - | - | - | 26 | 0.31* | -0.06 | - | - | - |
| GO:0007264 | Small GTPase mediated signal transduction | - | - | - | - | - | - | - | - | - | 14 | -0.14 | 0.79 |
Significant differences are marked with an asterisk. N, number of contributing genes; MCS, fractional intronic MCS density deviation (see text); IG, fractional igTEna deviation (see text).
Figure 1Analysis of MIR frequency in dog and opossum immune defense genes. MIR sequences were divided into mammalian-wide and metatherian/monotremata-specific. Immune response genes displayed significantly higher frequencies of both MIR types compared to the remaining genes. Box height represents sample interquartile range and the bold line depicts the median position. The whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box.
Figure 2Analysis of human MIR sequences associated with immune response genes. (a) Relative frequency at each position of MIR (n = 277), MIRb (n = 382) and MIR3 (n = 104) consensus sequences in immune response gene introns (red lines). Mean profiles and intervals corresponding to the 1st and 99th percentiles in 100 random sample frequency distributions are represented by black lines and grey areas, respectively. (b) The same as in (a) for MIRs located in intergenic regions. MIR, n = 239; MIRb, n = 345; MIR3, n = 97. Hatched lines delimit the MIR CORE region.
Figure 3Co-conservation profile of MIR sequences. Co-conservation frequency at each position of (a) MIR (n = 277), (b) MIRb (n = 382) and (c) MIR3 (n = 104) consensus sequences in immune response gene introns (red lines). Frequency intervals corresponding to the 1st and 99th percentiles in 100 random sample frequency distributions are represented by the black lines. (d) Co-conservation profiles of MIR sequences located in human introns; in this case, positions correspond to the alignment of the three MIR subtypes: MIR (black), MIRb (red) and MIR3 (blue).
Figure 4Gene-expression dependent variation in TE intronic abundance. Gene expression levels were derived from microarray data. (a) Lowess fit (solid line) and probability intervals (hatched lines) of TEna versus gene expression level (log transformed values) for the six TE families. (b) Lowess fit (solid line) and probability intervals (hatched lines) of intronic to intergenic relative TE frequency difference (see text) versus gene expression level (log transformed values).